We use cookies to ensure the best user experience. By using the page, you accept the usage of cookies. Read more
Skip to Content
FI
SV
Sidan finns inte på svenska. Tillbaka till den svenskspråkiga förstasidan av fimea.fi. Ångra
EN
Close navigation
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
    • Contact us
    • Forms
    • Organisation
    • What's new
    • Publications
    • Fees
    • Estimated processing times
    • Frequently asked questions
      • Clinical drug trials
      • Generic medicines
      • Invoicing
      • Marketing authorisations
      • Narcotics control
      • New EudraVigilance -system
    • Open positions
    • Open data
Open or close main menu
Medicine search
Contact Information
FI
SV
Sidan finns inte på svenska. Tillbaka till den svenskspråkiga förstasidan av fimea.fi. Ångra
EN

SearchBar

fimea.fi front page fimea.fi front page
About us

About us

  •  fimea.fi
    • For public
      • Safety of medicines
        • Adverse reactions
        • Inverted black triangle
        • Counterfeit medicines
        • Product defects
        • Drug interactions
      • Correct use of medicines
        • Package leaflet
        • Pain relievers
        • Medicines and dietary supplements
        • How to dispose of medicines
      • Generic products and generic substitution
      • Medicines and pregnancy
      • Medicines for children
        • Developing better medicines for children
      • Medication of the elderly
      • Travellers' medicines
      • Influenza
        • Influenza vaccinations
        • Antiviral medication
        • Pandemic
      • Vaccines
      • Internet trade in medicines
      • Reliability of pharmaceutical information
    • Databases and registers
      • Meds75+
        • Database
      • SmPCs and PLs
        • Human medicinal products
          • What does the SPC contain?
          • Search instructions for the SPC
        • Veterinary medicinal products
          • What does the SPC contain?
          • Search instructions for the SPC
        • Herbal medicinal products
          • What does the SPC contain?
          • Search instructions for the SPC
        • Package leaflets for medicine
        • Package leaflets for veterinary medicines
        • Package leaflets for herbal medicinal products
      • FimeaWeb
      • Consumption
      • Self-medication products
      • Basic register
        • Plasma-derived products with marketing authorisation
      • Substitutable medicinal products
        • Textfile for databases
        • Criteria used in compiling the list
      • Consumption information
    • Development and HTA
      • Assessment of pharmacotherapies (HTA)
        • Assessment of hospital-only medicinal products
        • Nordic collaboration (FINOSE)
        • Assessment reports (in Finnish)
      • Research
        • Research Network for Rational Pharmacotherapy (RATTI)
      • Medicines information
        • Medicines Information Network
        • High-quality medicines information
      • Interprofessional network
      • Patient advisory board
    • Marketing Authorisations
      • Marketing authorisation application
        • Finland as a Reference Member State in the decentralised procedure (DCP)
        • Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
        • Changing of Reference Member State duties to Finland
        • Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
        • Granted and cancelled marketing authorisations
        • Pending marketing authorisation applications
        • Biological Medicinal Products
        • Orphan drugs
        • Paediatric medicines
        • European Pharmacopoeia
        • Active substance names and standard terms
      • Renewals and variation applications
        • Renewals
        • Variation applications
        • Changes to labelling
        • Transferring a marketing authorisation to a new holder
        • Article 5 classification requests for variation applications
        • OTC application
      • Product Information
        • Summary of product characteristics
        • Package leaflet
        • Package labelling
        • Text templates
        • Braille and package leaflets for the visually impaired
        • Trade names of medicinal products
        • Strength
        • Translating influenza vaccines in Finland
      • Electronic marketing authorisation submissions
        • What's new
        • Instructions for electronic marketing authorisation submissions
        • Special characteristics of the electronic marketing authorisation process for veterinary medicines
      • Cancelling a marketing authorisation or registration and sunset clause
        • Cancelling a marketing authorisation or registration
        • Expiration of marketing authorisations and registrations (sunset clause)
        • Sunset clause - concepts
        • Sunset clause exemption
        • List of expired marketing authorisations and registrations
      • Introduction to market
      • Parallel import
      • Herbal remedies and medicinal products
        • Herbal medicinal products
        • Traditional herbal medicinal products
        • Homeopathic and anthroposophic preparations
      • Innovation Office
        • Informal Regulatory Guidance
        • Scientific Advice
      • Interchangeable medicinal products
      • Safety features
      • Other permits
        • Exemption
      • Frequently asked questions - marketing authorisations
        • Summary of Product Characteristics is to be available also in Swedish
        • Local representative
    • Pharmaceutical safety and information
      • Pharmaceutical safety
        • Reporting adverse reactions
      • Biological medicinal products
      • Biosimilars
        • Biosimilars in Finland
      • Regulation on Medicinal Products for Paediatric Use
        • Paediatric Committee
        • Paediatric Investigation Plan
        • Coordination and communication
        • Rewards and incentives
        • Symbol in the labels of medicinal products
    • Pharmacies
      • Pharmacy licences
        • How to apply for a pharmacy licence
        • Supervision Committee
      • Pharmacy tax
      • Special permits
        • How to apply for a special permit
        • Temporary special permit products
      • Manufacturing medicinal products
      • Schengen certificates
      • PIC/S GMP Guide
      • Dose-dispensing
    • Supervision
      • Pharmacovigilance
        • ICSR reporting to the EudraVigilance system
        • Product defects
        • Summaries of risk management plans
        • Fimea's Instructions to the National Implementation of the Directive 2010/84/EU
        • Product-specific risk minimisation material
      • Clinical Drug Trials
        • Notification of a clinical trial - EudraCT
        • Serious Unexpected Adverse Reactions in Clinical Trials (SUSARs)
      • Advertising of medicinal products
      • Classification
        • Principles of classification
        • Classification application
        • List of medicines
        • After classification
        • Private imports of medicinal products
      • Pharmaceutical industry
        • Licenses
          • Local pharmaceutical wholesale license holders
        • Registered brokers of medicinal products
      • Good Laboratory Practice (GLP)
      • Mandatory reserve supplies
        • Reports on quantities to be stocked as mandatory reserve supplies
        • List of products to be stocked as mandatory reserve supplies
        • Application for exemption to maintain lower stock levels
        • Special arrangements for fulfilment of the obligation to maintain mandatory reserve supplies
      • Establishments
        • Supervising blood services
        • Supervising tissue establishments
        • Supervision of organ activity
      • Certificates of a Pharmaceutical Product (CPP)
        • Applying for an export certificate
      • Narcotics control
        • Additional information to be submitted with narcotics licence applications
      • Batch-specific control
      • GMP certificates
      • Laboratory of Fimea
        • National and international collaboration
      • Legislation
        • International and EU legislation
        • European Pharmacopoeia
          • National pharmacopoeia documents
          • To users of the Pharmacopoeia
          • CEP Procedure
          • International Non-proprietary Names for Pharmaceutical Substances (INN)
        • National laws
        • Administrative regulations
        • Normative guidelines
        • Other guidelines
    • Veterinary
      • Marketing authorisation procedures
      • Special permits for compassionate use
        • Applying for special permit
        • FAQ
          • A Questions and answers on how to fill in the form
          • B Questions and answers regarding the technical aspects of permit application
          • C Questions and answers regarding the decision and the processing of the application
          • D Other questions and answers
        • Lists of veterinary medicinal products
      • Adverse effects
      • Consumption of veterinary antimicrobials
        • The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
      • Clinical trials on veterinary medicinal products
        • Immunological products
      • Withdrawal period and MRL
        • What is a withdrawal period?
        • MRL
        • Horses as food-producing animals
      • Private import
    • About us
      • Contact us
        • Change of address
        • Ordering of publications
        • Copyright
        • Contact
        • Personnel
        • Secure Mail
      • Forms
      • Organisation
        • Strategy
          • Our goals
          • Strategic framework
        • International representation
        • Fimea committees
      • What's new
        • News archive
        • Brexit
        • EU Presidency 2019
      • Publications
      • Fees
      • Estimated processing times
      • Frequently asked questions
        • Clinical drug trials
        • Generic medicines
        • Invoicing
        • Marketing authorisations
          • Summary of Product Characteristics is to be available also in Swedish
        • Narcotics control
        • New EudraVigilance -system
      • Open positions
      • Open data
  • fimea.fi
  • About us
  • Frequently asked questions
  • Invoicing

Invoicing

Suomeksi

Frequently asked questions

  • How soon after submitting the application will I receive the invoice?
  • How should I provide my invoicing information?
  • Can I provide multiple invoicing addresses?
  • What is the due date for the annual fees for marketing authorisations?
Page 1
1
Previous
Previous
Next
Next
RSS (Opens New Window)(Opens New Window)
  • fimea.fi
  • About us
  • Frequently asked questions
  • Invoicing
Print
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
  • Contact us
  • Frequently asked questions
  • Forms
fimea
  • Twitter
  • P.O. Box 55, FI-00034 FIMEA, FINLAND
  • Switchboard: +358 29 522 3341
  • firstname.lastname@fimea.fi
© Fimea 2018
The Finnish Medicines Agency Fimea is the national competent authority for regulating pharmaceuticals. As a central administrative agency operating under the Ministry of Social Affairs and Health it promotes the health and safety of the population by regulating medicinal, blood and tissue products, and by developing the pharmaceuticals sector.
http://stm.fi/ The Ministry of Social Affairs and Health
fimea.fi Finnish Medicines Agency Fimea
thl.fi National Institute for Health and Welfare
ttl.fi Finnish Institute of Occupational Health
tyosuojelu.fi Työsuojeluhallinto
valvira.fi National Authority for Welfare and Health
stuk.fi Radiation and Nuclear Safety Authority Radiation and Nuclear Safety Authority